Clinical Trial Update: Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid [Phase 2]

View source ↗

Summary

Phase 2 multi-dose safety and pharmacodynamic study of SEL-212/SEL-037 in symptomatic gout with hyperuricemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gout
• Hyperuricemia

Drugs mentioned

• SEL-037 (SEL-037)
• SEL-212

Snippet

Sponsor: Selecta Biosciences, Inc. | Conditions: Gout Chronic, Hyperuricemia | Phase 2 | Status: COMPLETED | Results posted: 2022-02-14